Aspire BioPharma is trading 6.4% lower at $8.31 in pre-market, with no clear catalyst identified. - The supplied pre-market price compares with the October 5 close of $8.88. - No fresh company-specific announcement was found; the reported September 29 auditor change is prior context, not an established cause. - U.S. index futures were higher pre-market as yields and oil prices dipped, according to Reuters, leaving the decline’s reason unclear against broader market direction.